The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells
Open accessAbstract
The goal of this study was to characterize the agonist pharmacology of human 5‐HT 2A, 5‐HT 2B and 5‐HT 2C (VSV) receptors expressed in CHO‐K1 (Chinese hamster ovary) cells. We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addition of agonists. Stimulation of all three receptors by 5‐HT caused a robust concentration dependent increase in intracellular calcium levels. No such effect was observed from non‐transfected control CHO‐K1 cells. The rank order of potency of agonists at the different receptor subtypes varied. Tryptamines, BW‐723C86, d‐norfenfluramine, Ro 60‐0175 and LSD exhibited the following rank order of potency; 5‐HT 2B>5‐HT 2C>5‐HT 2A. Piperazines such as m‐Chlorophenylpiperazine (mCPP), ORG‐12962, MK‐212 and also ORG‐37684 exhibited a rank order of potency of 5‐HT 2C>5‐HT 2B>5‐HT 2A. The phenylisopropylamines DOI and DOB had a rank order of 5‐HT 2A>5‐HT 2B>5‐HT 2C. Many agonists tested had partial agonist actions when compared to 5‐HT, and a wide range of relative efficacies were exhibited, which was cell line dependent. For example, mCPP had a relative efficacy of 65% at 5‐HT 2C receptors but <25% at either 5‐HT 2A or 5‐HT 2B receptors. Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex. Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same experiment using the same assay conditions and parental cell lines. British Journal of Pharmacology (1999) 128, 13–20; doi:10.1038/sj.bjp.0702751
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,003
Regulation of serotonin-2C receptor G-protein coupling by RNA editing
Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., & Emeson, R. B. (1997) · Nature · doi:10.1038/387303a0 · Cited by 1,010 · cited 3×
“…of this has been reported to be a reduced a nity and e cacy of agonists at the edited isoforms relative to the unedited INI isoform, with a concomitant reduced constitutive activity of the receptor when expressed in cell lines (Burns et al., 1997; Niswender et al., 1998; 1999; Iyer et al., 1998).”
BackgroundPompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881
A proposed new nomenclature for 5-HT receptors
Humphrey, P. P. A., Hartig, P., & Hoyer, D. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90016-d · Cited by 549
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity
Niswender, C. M., Copeland, S. C., Herrick-Davis, K., Emeson, R. B., & Sanders-Bush, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9472 · Cited by 363
Titeler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343
5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37669-4 · Cited by 334
Bonhaus, D. W., Bach, C., DeSouza, A., Salazar, F. H. R., Matsuoka, B. D., Zuppan, P., Chan, H. W., & Eglen, R. M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb14977.x · Cited by 305
Receptors for 5-Hydroxytryptamine: Current perspectives on classification and nomenclature
Martin, G. R., & Humphrey, P. P. A. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90058-2 · Cited by 305
Roth, B. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00019-9 · Cited by 287
Conn, P. J., & Sanders-Bush, E. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39117-2 · Cited by 219
Duxon, M. S., Flanigan, T. P., Reavley, A. C., Baxter, G. S., Blackburn, T. P., & Fone, K. C. F. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00480-0 · Cited by 210
FLIPR: A New Instrument for Accurate, High Throughput Optical Screening
Schroeder, K. S., & Neagle, B. D. (1996) · SLAS Discovery · doi:10.1177/108705719600100205 · Cited by 198
Kursar, J. D., Nelson, D. L., Wainscott, D. B., & Baez, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09676-2 · Cited by 170
Cloning and functional characterization of the human 5‐HT2B serotonin receptor
Schmuck, K., Ullmer, C., Engels, P., & Lübbert, H. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80590-3 · Cited by 158
Marek, G. J., & Aghajanian, G. K. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20792-3 · Cited by 156
Agonist activity of LSD and lisuride at cloned 5HT 2A and 5HT 2C receptors
Egan, C. T., Herrick‐Davis, K., Miller, K. J., Glennon, R. A., & Teitler, M. (1998) · Psychopharmacology · doi:10.1007/s002130050585 · Cited by 125
BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats
Kennett, G. A., Ainsworth, K., Trail, B. K., & Blackburn, T. P. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00171-2 · Cited by 118
Wainscott, D. B., Lucaites, V. L., Kursar, J. D., Baez, M., & Nelson, D. L. G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12346-x · Cited by 118
Effects of the 5‐HT2B receptor agonist, BW 723C86, on three rat models of anxiety
Kennett, G. A., Bright, F., Trail, B. K., et al. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15304.x · Cited by 111
Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?
Dourish, C. T. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00212.x · Cited by 108
Johnson, M. P., Loncharich, R. J., Baez, M., & Nelson, D. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09924-9 · Cited by 104
Bös, M., Jenck, F., Martin, J. R., Moreau, J., Sleight, A. J., Wichmann, J., & Widmer, U. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970030l · Cited by 97
Identification and Characterization of RNA Editing Events within the 5‐HT2C Receptora
Niswender, C. M., Sanders‐Bush, E., & Emeson, R. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10171.x · Cited by 90
Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists.
Westphal, R. S., & Sanders‐Bush, E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09836-0 · Cited by 86
Receptor subtype and density determine the coupling repertoire of the 5-ht2 receptor subfamily
Lucaites, V. L., Nelson, D. L. G., Wainscott, D. B., & Baez, M. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00423-7 · Cited by 72
Giles, H., Lansdell, S. J., Bolofo, M. L., Wilson, H. L., & Martin, G. R. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb16705.x · Cited by 64
Novel discriminatory ligands for 5-HT2B receptors
Baxter, G. S. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00087-3 · Cited by 57
Newton, R. A., PHIPPS, S. L., Flanigan, T. P., Newberry, N. R., Carey, J. E., Kumar, C. S., McDonald, B., Chen, C., & Elliott, J. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67062521.x · Cited by 46
Nelson, D. L., Lucaites, V. L., Audia, J. E., et al. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38269-8 · Cited by 44
Endogenous serotonin-2A and -2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium
Saucier, C., Morris, S. J., & Albert, P. R. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00244-5 · Cited by 40
m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor
Thomas, D. R., Gager, T., Holland, V. A., Brown, A. M., & Wood, M. D. (1996) · Neuroreport · doi:10.1097/00001756-199606170-00002 · Cited by 40
Johnson, M. P., Audia, J. E., Nissen, J. S., & Nelson, D. L. G. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90983-o · Cited by 25
Cited by
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression
Celada, P., Puig, M. V., Amargós-Bosch, M., Adell, A., & Artigas, F. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0427 · Cited by 519
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
Gregg, T. R., & Siegel, A. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00150-0 · Cited by 314
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
Metadata
- Authors
- Porter, R. H. P., Benwell, K. R., Lamb, H., Malcolm, C. S., Allen, N. H., Revell, D. F., Adams, D. R., & Sheardown, M. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1999-09
- Volume
- 128
- Issue
- 1
- Pages
- 13-20
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2079825367
- Cited by
- 358
- References
- 34
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.